An early human study suggests immunotherapy for glioblastoma may require targeting the immune suppressive effects of MDSCs along with immune activation tactics to overcome tumor-induced immunosuppression.
Laser and estrogen therapies are similarly effective treatments for genitourinary syndrome of menopause, according to a recently published, multi-institutional trial. Gynecologist and principal investigator Marie Fidela Paraiso, MD, discusses the trial and the setbacks the team has encountered, despite the positive results.
Cleveland Clinic Cancer Center’s new CHIP Clinic will screen and monitor patients with potentially disease-causing somatic mutations called clonal hematopoiesis of indeterminate potential (CHIP) in blood or bone marrow cells.
The emergence of immune-related adverse events (irAEs) from cancer immunotherapy represents a formidable challenge for rheumatologists. Rheumatologist Leonard Calabrese, DO, explains a new classification system for irAEs that may help to focus discussions of these heterogeneous complications.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Atul F. Kamath, MD, Director of Cleveland Clinic’s Center for Hip Preservation, reviews a complex case involving a young adult patient with trauma-related osteonecrosis.
A toddler with Eagle-Barrett syndrome presents for follow-up evaluation with bilateral cryptorchidism, abdominal wall muscle deficiency and urinary tract abnormalities. The patient has urine retention, vesicoureteral reflux and sub-optimal kidney function. What intervention is appropriate at this time?
A 64-year-old transgender woman with recurrent rectoneovaginal fistula (RnVF) presents for care following penile skin inversion neovaginoplasty at an outside institution. Exam reveals a 2- to 3-cm fistula at the cephalad nevoagnial, roughly 6 cm proximal to the anorectal ring. What are the options for surgical repair?
A new clinical trial for metastatic prostate cancer aims to target the primary tumor while also treating the metastatic disease, an approach that has become common in Europe but hasn’t been widely used in the U.S.
Launch of the phase 3 Lp(a) HORIZON trial of a novel antisense oligonucleotide therapy for reducing elevated Lp(a) may signal the first real therapeutic progress on a final frontier of lipid management.
Cleveland Clinic announced the appointment of Thomas E. Mroz, MD, as chair of the Orthopaedic & Rheumatologic Institute. Dr. Mroz, who specializes in minimally invasive surgery and cervical spine surgery, will oversee more than 478 caregivers and 125 staff physicians in the institute.